# US 2026/0242469 A1 · Anti-cd2 antibodies for amyotrophic lateral sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242469 A1
- Document ID: US20260242469A1
- Status: Published application
- Kind: A1
- Application number: 19/160,969
- Filed: 2024-02-29
- Published: 2026-08-20
- Earliest claimed: 2023-03-01
- Assignees: Zelarion Malta Limited
- Applicants: Zelarion Malta Limited
- Inventors: Erik BERGLUND; David BERGLUND; Alan Slade
- Web page: https://patentgrep.com/patent/US20260242469A1

## CPC

- C07K 16/2806: {against CD2}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein is an anti-CD2 antibody or antigen binding fragment thereof for treating and/or preventing ALS in a subject in need thereof.

## Claims

### Claim 1

A method of treating, preventing or ameliorating at least one symptom associated with amyotrophic lateral sclerosis (ALS) in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of a recombinant anti-CD2 antibody or an antigen binding fragment thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the recombinant anti-CD2 antibody comprises:
(a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 3;
(b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 4;
(c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 5;
(d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 6;
(e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 7; and
(f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 8.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the anti-CD2 antibody or antigen binding fragment thereof comprises an amino acid sequence that is about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the anti-CD2 antibody or antigen binding fragment thereof comprises an amino acid sequence that is about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the heavy chain of the anti-CD2 antibody or antigen binding fragment thereof is encoded by a nucleotide sequence comprising about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 16.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the light chain of the anti-CD2 antibody or antigen binding fragment thereof is encoded by a nucleotide sequence comprising about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 17.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the recombinant anti-CD2 antibody or an antigen binding fragment thereof comprises a heavy chain constant region comprising an amino acid sequence that is about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 9, 10, 11, 12, or 13.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the recombinant anti-CD2 antibody or an antigen binding fragment thereof comprises a light chain constant region comprising an amino acid sequence that is about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 14 or 15.

### Claim 9 (depends on 1)

The method of claim 1, wherein the recombinant anti-CD2 antibody comprises:
(a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 24;
(b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 25;
(c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 26;
(d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 27;
(e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 28; and
(f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 29.

### Claim 10 (depends on 1, 9)

The method of claim 1 or claim 9, wherein the anti-CD2 antibody or antigen binding fragment thereof comprises an amino acid sequence that is about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 22.

### Claim 11 (depends on 1, 9, 10)

The method of any one of claim 1, 9 or 10, wherein the anti-CD2 antibody or antigen binding fragment thereof comprises an amino acid sequence that is about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 23.

### Claim 12 (depends on 1, 9, 10, 11)

The method of any one of claim 1 or 9-11, wherein the recombinant anti-CD2 antibody or an antigen binding fragment thereof comprises a heavy chain constant region comprising an amino acid sequence that is about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 30.

### Claim 13 (depends on 1, 9, 10, 11)

The method of any one of claim 1 or 9-11, wherein the recombinant anti-CD2 antibody or an antigen binding fragment thereof comprises a light chain constant region comprising an amino acid sequence that is about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 31.

### Claim 14 (depends on 1)

The method of claim 1, wherein the anti-CD2 antibody or antigen binding fragment thereof comprises an amino acid sequence that is about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 31, 32, 33, 34, or 35.

### Claim 15 (depends on 1, 14)

The method of claim 1 or claim 14, wherein the anti-CD2 antibody or antigen binding fragment thereof comprises an amino acid sequence that is about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 36, 37, 38, 39, or 40.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the anti-CD2 antibody or antigen binding fragment thereof comprises an additional CH2 domain.

### Claim 17 (depends on 16)

The method of claim 16, wherein the additional CH2 domain comprises an amino acid sequence that is about or at least about 80%, 85%, 90%, 95%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 18 or 19.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the anti-CD2 antibody or antigen binding fragment thereof comprises an additional CH3 domain.

### Claim 19 (depends on 18)

The method of claim 18, wherein the additional CH3 domain comprises an amino acid sequence that is about or at least about 80%, 85%, 90%, 95%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 20 or 21.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the anti-CD2 antibody or antigen binding fragment thereof is a humanized antibody.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the anti-CD2 antibody or antigen binding fragment thereof is an IgG1.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the anti-CD2 antibody or antigen binding fragment thereof is an IgG4.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the effective amount is sufficient to:
(a) increase the subject's Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) total score by at least 0.5 points;
(b) maintain the subject's ALSFRS-R total score; or
(c) slow the subject's disease progression rate by at least 0.5 ALSFRS-R/month, as compared to the ALSFRS-R total score obtained from the subject prior to the administering.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the effective amount is sufficient to increase life expectancy of the subject after the administering as compared to a subject having a similar diagnosis and rate of disease progression that was not administered the effective amount of a recombinant anti-CD2 antibody or an antigen binding fragment thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein the increase is an increase of about or at least about a month, 3 months, 6 months, a year, 2 years, 3 years, 4 years, 5 years, or greater than 5 years.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the effective amount is sufficient to increase the percentage of the ratio of regulatory T cells to effector T cells (Treg:Teff) in a biological sample from the subject after the administering as compared to the percentage of Treg:Teff ratio in a biological sample obtained from the subject prior to the administering.

### Claim 27 (depends on 26)

The method of claim 26, wherein the increase is an increase of about or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or greater than 100%.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein the effective amount is sufficient to decrease circulating T-cells in a biological sample from the subject after the administering as compared to the amount of circulating T-cells in a biological sample obtained from the subject prior to the administering.

### Claim 29 (depends on 28)

The method of claim 28, wherein the decrease is a decrease of about or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the effective amount is sufficient to decrease natural killer (NK)-cells in a biological sample from the subject after the administering as compared to the amount of NK-cells in a biological sample obtained from the subject prior to the administering.

### Claim 31 (depends on 30)

The method of claim 30, wherein the decrease is a decrease of about or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein the effective amount is sufficient to increase regulatory T cells in a biological sample from the subject after the administering as compared to the amount of regulatory T cells in a biological sample obtained from the subject prior to the administering.

### Claim 33 (depends on 32)

The method of claim 32, wherein the increase is an increase of about or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or greater than 100%.

### Claim 34 (depends on 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 26-33, wherein a biological sample comprises the subject's serum, peripheral blood mononuclear cells (PBMCs), cerebrospinal fluid (CSF), or any combination thereof.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein subject in need thereof has been diagnosed as having familial ALS or sporadic ALS.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein subject in need thereof has been diagnosed as having ALS within 36 months or less.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein subject in need thereof has been diagnosed as having ALS within 24 months or less.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 1-37, wherein the at least one symptom associated with ALS comprises dyspnea, orthopnea, muscle weakness, dysphagia, dysarthria, or a combination of two or more thereof.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1-38, wherein the administering to the subject comprises intravenous administration, intrathecal administration, or both.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 1-39, wherein the subject is currently being treated or has been previously treated with one or more ALS treatments.

### Claim 41 (depends on 40)

The method of claim 40, wherein the one or more ALS treatments comprises riluzole, tauroursodeoxycholic acid (TUDCA), sodium phenylbutyrate, or any combination thereof.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 1-41, wherein the administering is for about or at least about 26 weeks.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 1-41, wherein the administering is for about or at least about 24 weeks.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 1-43, wherein the administering is once every week, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, once every 6 weeks, once every 7 weeks, once every 8 weeks, once every 9 weeks, once every 10 weeks, once every 11 weeks, once every 12 weeks, once every 13 weeks, once every 14 weeks, once every 15 weeks, once every 16 weeks, once every 3 months, once every 3.5 months, once every 4 months, once every 4.5 months, once every 5 months, once every 5.5 months, or once every 6 months.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, wherein the effective amount is sufficient to achieve about 10 ng/ml recombinant anti-CD2 antibody or an antigen binding fragment thereof in the subject's CSF at a steady state.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 1-45, wherein the effective amount is sufficient to achieve a trough concentration (C0) greater than about 19 g/mL recombinant anti-CD2 antibody or an antigen binding fragment thereof in the subject.

### Claim 47 (depends on 45, 46)

The method of claim 45 or claim 46, wherein the effective amount is sufficient to achieve about 10 ng/ml recombinant anti-CD2 antibody or an antigen binding fragment thereof in the subject's CSF at a steady state for at least 30 days.

### Claim 48 (depends on 45, 46)

The method of claim 45 or claim 46, wherein the effective amount is sufficient to achieve about 10 ng/ml recombinant anti-CD2 antibody or an antigen binding fragment thereof in the subject's CSF at a steady state for at least 50 days.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 1-48, wherein the effective amount is from about 0.01 mg/kg to about 100 mg/kg and the administering is about every 4-14 weeks for a period of time sufficient to treat, prevent, or ameliorate at least one symptom associated with ALS in the subject.

### Claim 50 (depends on 49)

The method of claim 49, wherein the administering occurs three times between the first administration and the last administration for a total of five administrations.

### Claim 51 (depends on 50)

The method of claim 50, wherein the last administration is 26 weeks after the first administration.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 1-48, wherein the effective amount is from about 0.01 mg/kg to about 100 mg/kg and the administering is about every 4-16 weeks for a period of time sufficient to treat, prevent, or ameliorate at least one symptom associated with ALS in the subject.

### Claim 53 (depends on 52)

The method of claim 52, wherein the administering occurs two times between the first administration and the last administration for a total of four administrations.

### Claim 54 (depends on 53)

The method of claim 53, wherein the last administration is 24 weeks after the first administration.
